Figure 2
From: The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Histopathology example of a patient who maintained the HER2 status both in early and metastatic biopsy. At breast cancer diagnosis (a) the pathologists’ report called for “Membrane staining that is complete, intense and in ˃ 10% of tumor cells. IHC: 3 + .” At relapse (b), a cutaneous lesion in the ipsilateral breast was biopsied and the pathologists’ report exactly reproduced the prior one.
